ICRM
EW icon

Insight Capital Research & Management’s Edwards Lifesciences EW Stock Holding History

Insight Capital Research & Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14,079
Closed -$555K – 116
2017
Q2 		$555K Buy
+14,079
New +$514K 0.33% 91
2017
Q1 		– Sell
-13,740
Closed -$429K – 88
2016
Q4 		$429K Sell
13,740
-59,763
-81% -$1.94M 0.23% 95
2016
Q3 		$2.95M Sell
73,503
-309
-0.4% -$11.6K 1.32% 28
2016
Q2 		$2.45M Buy
+73,812
New +$2.53M 0.86% 68

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Insight Capital Research & Management's EW Position: Q3 2017 in Review

Insight Capital Research & Management sold out of Edwards Lifesciences (EW) in Q3 2017, closing a stake of 14,079 shares — an estimated $555K sold.

Insight Capital Research & Management first reported a position in EW in Q2 2016 and held it in 4 quarters. The position peaked at $2.95M in Q3 2016. 739 funds tracked by Wall St. Rank hold EW as of Q3 2017.

  • Insight Capital Research & Management reported no remaining Edwards Lifesciences position as of Q3 2017 after selling out during the quarter.
  • Insight Capital Research & Management sold 14,079 Edwards Lifesciences shares in Q3 2017, an estimated $555K.
  • Insight Capital Research & Management first reported a position in Edwards Lifesciences in Q2 2016 and held it in 4 quarters.
  • Insight Capital Research & Management's Edwards Lifesciences position peaked at $2.95M in Q3 2016.
  • 739 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2017.

Based on Insight Capital Research & Management's 13F filing for Q3 2017, filed 15 Nov 2017.